exRNAdisease

Entry Detail

---



General Information

Database ID: exR0275746 RNA Name: hsa-miR-541-3p RNA Type: miRNA Chromosome: chr14 Starnd: + Coordinate: Start Site(bp): 101064548 End Site(bp): 101064569 External Links: hsa-miR-541-3p

Disease Information

Disease Name: Advanced Adenoma Disease Category: Cancers MeSH ID: D000236 Type: Neoplasms/Neoplasms, Glandular and Epithelial Alias: Adenoma//Adenomas//Adenoma, Follicular//Adenomas, Follicular//Follicular Adenoma//Follicular Adenomas//Adenoma, Trabecular//Adenomas, Trabecular//Trabecular Adenoma//Trabecular Adenomas//Adenoma, Monomorphic//Adenomas, Monomorphic//Monomorphic Adenoma//Monomorphic Adenomas//Adenoma, Papillary//Adenomas, Papillary//Papillary Adenoma//Papillary Adenomas//Adenoma, Basal Cell//Adenomas, Basal Cell//Basal Cell Adenoma//Basal Cell Adenomas//Adenoma, Microcystic//Adenomas, Microcystic//Microcystic Adenoma//Microcystic Adenomas

Expression Detail

GEO ID: GSE25609 Description: Plasma microRNA profiling by microarray elucidates several candidate biomarkers for colorectal cancer screening Experimental Design: Cancer vs Control Case Disease Type: Advanced Adenoma Case Disease SubType: NA Case Sample: Advanced Adenoma Post surgery Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand REPIN1 chr7 150368189 150374044 + HOXD11 chr2 176104216 176109754 + LY6E chr8 143017982 143023832 + FASN chr17 82078338 82098294 - M6PR chr12 8940361 8949761 - TOM1L2 chr17 17843511 17972422 - ACACA chr17 37084992 37406836 - TAF4 chr20 61953469 62065810 - MID1IP1 chrX 38801432 38806537 + FBXO46 chr19 45710629 45730896 - BICRA chr19 47608196 47703277 + CALR chr19 12938578 12944489 + ARHGDIA chr17 81867721 81871378 - UCP2 chr11 73974672 73983246 - FKBP1A chr20 1368978 1393172 - SLC6A6 chr3 14402576 14489349 + NFIX chr19 12995608 13098796 + ADGRL1 chr19 14147743 14206187 - NID1 chr1 235975830 236065109 - CAPZB chr1 19338775 19485539 - AGRN chr1 1020120 1056118 + AXL chr19 41219223 41261766 + MAFG chr17 81918270 81927735 - PKM chr15 72199029 72231822 - IGFBP5 chr2 216672105 216695549 - MIGA2 chr9 129036621 129072082 + ZMIZ1 chr10 79068966 79316528 + PRRC2B chr9 131373636 131500197 + ACVR1B chr12 51951699 51997078 + DMWD chr19 45782947 45792845 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000417 chr12 69644908 69656342 + hsa_circ_0000642 chr15 80390757 80415142 + hsa_circ_0000816 chr17 80521229 80526077 + hsa_circ_0000643 chr15 80412669 80415142 + hsa_circ_0000943 chr19 47421744 47440665 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC239868.1 chr1 149861271 149862504 + AL035458.2 chr20 34234840 34281173 - AL356488.2 chr1 109100193 109100619 + NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - OIP5-AS1 chr15 41283990 41309737 + STAG3L5P-PVRIG2P-PILRB chr7 100336104 100367831 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE25609 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 826 Sample treatment protocol: Briefly, samples were centrifuged at 1,600×g for 10 min at 4 ºC to spin down blood cells, and plasma was transferred into new tubes, followed by further centrifugation at 16,000×g for 10 minutes at 4ºC to completely remove cellular components. RNA Extract protocol: NA RNA library preparation protocol: Biotinylated cDNA were prepared with the Illumina® TotalPrep™ RNA Amplification Kit (Ambion).

Reference

PMID: 23267864 Title: Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study Author: Gir¨¢ldez MD, Lozano JJ, Ram¨ªrez G, Hijona E, Bujanda L, Castells A, Gironella M Journal: Clin Gastroenterol Hepatol. 2013 Jun;11(6):681-8.e3. Description: We investigated whether plasma levels of miRNA can differentiate patients with CRC from healthy individuals. We also investigated whether plasma samples from patients with premalignant neoplastic lesions, such as advanced adenomas (AAs), also had a different expression pattern of miRNAs.